Insmed Incorporated
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Insmed Incorporated sits in the top decile of US sponsors by registered trial count (#526 of 15,742 sponsors by registered trial count).
Insmed Incorporated: 31 sponsored US clinical trials, 2 recruiting.
Insmed Incorporated sponsors 31 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 25 completed. 5 of these trials are in Phase 3-4 (later-stage) and 26 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Laron Syndrome, with 1 trials.
Top-decile sponsor footprint
Insmed Incorporated ranks in the top decile of sponsors by registered trial count (#526 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
25 of 27 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (92.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
31 total, page 1 of 1
A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
NCT07481981
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT07179380
A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)
NCT06685835
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)
NCT05649748
A Study to Assess the Relative Bioavailability After a Single Inhalation Administration of Treprostinil Palmitil Inhalation Powder (TPIP) Formulation 2 (F2) to TPIP Formulation 3 (F3) in Healthy Participants
NCT07102316
A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets in Healthy Participants
NCT06344728
A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy Participants
NCT06178783
A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
NCT06013241
A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants
NCT05965570
A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy Participants
NCT05826574
A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment
NCT05517525
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
NCT05147805
A Study to Investigate the Effects of Brensocatib on QT Interval in Healthy Participants
NCT05355935
A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)
NCT04791514
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis
NCT05090904
A Study of the Absorption, Metabolism, and Excretion of [14C]-Brensocatib Following a Single Oral Administration in Healthy Male Participants
NCT05652257
A Study of Brensocatib Following a Single Oral Administration in Participants With or Without Renal Impairment
NCT05673603
Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex
NCT04677569
Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex
NCT04677543
A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis
NCT04594369
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants
NCT06091579
A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of INS1007 in Healthy Japanese and Caucasian Participants
NCT05927597
Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis
NCT03218917
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyvaso® Cohort in Healthy Participants
NCT06193031
Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria
NCT01315236
Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa.
NCT00775138
Safety/Tolerability Study of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa
NCT00558844
Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1
NCT00577577
Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung
NCT00102531
IGF-I/IGFBP-3 Therapy in Children and Adolescents With Growth Hormone Insenitivity Syndrome (GHIS) Such as Laron Syndrome
NCT00368173
Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan Syndrome
NCT00351221
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 14 |
| Phase 2 | 12 |
| Phase 3 | 5 |
What is open in the Insmed Incorporated pipeline
2 recruiting of 31 indexed (6% open); 25 completed (81%).
Phase mix: 5 late (III/IV) vs 26 early (I/II) (early-phase heavy).
Top condition: Laron Syndrome (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Insmed Incorporated: open-pipeline peers nationwide
Peers matched on 31 registered trials and 6% open enrollment, not the therapeutic-area sidebar.
Insmed Incorporated sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 31 trials (± recruiting share)
- Children's Hospitals and Clinics of Minnesota · 31 trials · 10% recruiting
- Cook Group Incorporated · 31 trials · 0% recruiting
- Cytokinetics · 31 trials · 10% recruiting
- Halozyme Therapeutics · 31 trials · 3% recruiting
Sponsors near 6% open enrollment (± trial volume)
- Alliance for Clinical Trials in Oncology · 7% recruiting · 446 trials
- National Institutes of Health Clinical Center (CC) · 7% recruiting · 338 trials
- Hennepin Healthcare Research Institute · 6% recruiting · 63 trials
- NICHD Neonatal Research Network · 7% recruiting · 61 trials
Related
What to do with this Insmed Incorporated page
31 registered trials is a research-attention snapshot, not an endorsement of Insmed Incorporated or any single study.
- 2 of Insmed Incorporated's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Laron Syndrome is the condition Insmed Incorporated studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Laron Syndrome trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Insmed Incorporated pipeline card: 31 registered trials from official public datasets.Report a data error.